Evidence map›Paper›PMID 32999046›Full record

ArticleMolecular cancer therapeutics2020

Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy

Arsheed A Ganaie, Adrian P Mansini, Tabish Hussain, Arpit Rao, Hifzur R Siddique, Ashraf Shabaneh, Marina G Ferrari, Paari Murugan, Jörg Klingelhöfer, Jinhua Wang and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Follow-Up Biomarkers in the Evolution of Prostate Cancer, Levels ofInternational journal of molecular sciences · 2022
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Arsheed A GanaieDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Adrian P MansiniDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-0857-0556
Tabish HussainDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Arpit RaoDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Hifzur R SiddiqueDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-8736-0487
Ashraf ShabanehInstitute for Health Informatics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Marina G FerrariDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-6295-5695
Paari MuruganDepartment of Laboratory Medicine and Pathology, Medical School, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0003-4706-213X
Jörg KlingelhöferDanish Cancer Society Research Center, Copenhagen, Denmark.ORCID 0000-0001-5928-4755
Jinhua WangInstitute for Health Informatics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Noona AmbartsumianDanish Cancer Society Research Center, Copenhagen, Denmark.
Christopher A WarlickDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Badrinath R KonetyDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Mohammad SaleemDepartment of Urology, Medical School, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. msbhat@umn.edu.
University of Minnesota Medical Center · USUniversity of Minnesota · USUniversity of Copenhagen · DKAligarh Muslim University · INRush University Medical Center · US

Funding

Research CoreU54MD008620 · NIMHD · UNIVERSITY OF MINNESOTA · PI BRADY, SONYA S, SHIKANY, JAMES M · 2013 to 2017
$13.5M
Novel targeted chemo/immunotherapy approach for localized and metastatic CaPR01CA193739 · NCI · UNIVERSITY OF MINNESOTA · PI BHAT, MOHAMMAD SALEEM · 2016 to 2020
$1.8M
Novel gene that determines metastatic phenotype in African-American men with PCaR21CA184685 · NCI · UNIVERSITY OF MINNESOTA · PI BHAT, MOHAMMAD SALEEM · 2015 to 2016
$582k
NCI NIH HHS R01 CA193739NCI NIH HHS R21 CA184685NIMHD NIH HHS U54 MD008620
6 · The paper itself

Abstract

S100A4 oncoprotein plays a critical role during prostate cancer progression and induces immunosuppression in host tissues. We hypothesized that S100A4-regulated oncogenic activity in immunosuppressed prostate tumors promotes growth of neoplastic cells, which are likely to become aggressive. In the current study, we investigated whether biopsy-

Indexed as

Antineoplastic Agents, ImmunologicalBiomarkers, TumorCD4-Positive T-LymphocytesCytokinesHumansImmunomodulationLiquid BiopsyLymphocyte CountMalePrognosisProstatic NeoplasmsS100 Calcium-Binding Protein A4Treatment OutcomeAntineoplastic Agents, ImmunologicalBiomarkers, TumorCytokinesS100A4 protein, humanS100 Calcium-Binding Protein A4

Identifiers

PMID32999046
PMCPMC9437909
OpenAlexW3090959990

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.